Bhutan In-vitro Diagnostics market revenue is projected to grow at a CAGR of 4.9% during 2025–2031

Clinical chemistry segment by Type held the highest revenue share in Bhutan In-vitro Diagnostics Market -6Wresearch

The clinical chemistry segment held the largest share of the Bhutan In-Vitro Diagnostics Market, supported by high testing volumes for liver, kidney, lipid, thyroid, and metabolic panels. Healthcare providers relied on these routine biochemical tests as the backbone of diagnostic evaluation, prompting continuous demand for automated analyzers and reagents. Widespread adoption across public hospitals, private diagnostic centres, and urban clinics further reinforced the dominance of clinical chemistry as the most essential and frequently utilized testing category in the country.

According to 6Wresearch, Bhutan In-vitro Diagnostics Market revenue is projected to grow at a CAGR of 4.9% during 2025–2031. Between 2021 and 2024, Bhutan IVD market expanded steadily as rising non-communicable diseases and broader public-health screening programs increased testing requirements across the country. Government data and WHO reports indicate growing prevalence of hypertension, diabetes, kidney disorders, and cancers conditions that depend on routine laboratory diagnostics for detection and monitoring. Bhutan’s healthcare system, supported by a national network of hospitals and primary health centers and fully reliant on imported analyzers and reagents, saw higher diagnostic utilization as the Health Flagship initiatives intensified screening for cancer, diabetes, and kidney-related conditions. Alongside this, digital-health upgrades under the Royal Government strengthened teleconsultation capacity, data reporting, and clinical workflow efficiency, contributing to higher diagnostic throughput across public facilities.

Between 2025 and 2031, Bhutan’s IVD market is expected to grow further as the country scales digital-health infrastructure, expands NCD screening, and increases public-health expenditure. Ongoing digital-health programmes aim to strengthen electronic health records, laboratory information systems, and telehealth services across hospitals and primary-care centers, widening access to diagnostics in remote gewogs. Continued implementation of the Health Flagship initiatives for cancer, diabetes, and kidney disease will maintain sustained demand for laboratory tests essential for early detection, staging, and long-term monitoring. Rising public-sector procurement and alignment with WHO’s Essential Diagnostics guidance will drive adoption of automated chemistry, immunoassay, and rapid-test platforms across district hospitals. In combination, these factors will position IVD as a central enabler of Bhutan’s preventive and evidence-driven healthcare ecosystem through 2031.

According to Sumit, Senior Research Analyst, 6Wresearch, the infectious disease application segment accounted for a significant share of Bhutan's In-Vitro Diagnostics Market. This dominance is driven by the country’s ongoing challenges with infectious diseases, including malaria, tuberculosis, hepatitis, and dengue. The high demand for diagnostic testing for these diseases is supported by public health initiatives and government reforms. With the increasing adoption of rapid diagnostic tests and expanding diagnostic networks, the need for infectious disease testing is expected to remain strong in the coming years.

Bhutan In-vitro Diagnostics Market (2025-2031) report provides an in-depth analysis with 23 figures and 6 tables, covered in 76 pages. The report thoroughly covers the market by product, type, application, and end user. The Bhutan In-vitro Diagnostics Market outlook report provides an unbiased and detailed analysis of the ongoing trends, opportunities/high growth areas, and market drivers, which would help the stakeholders to devise and align their market strategies according to the current and future market dynamics.